{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:46:28Z","timestamp":1793303188896,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The cyclic GMP\u2013AMP synthase\u2013stimulator of interferon genes (cGAS\u2013STING) pathway is critical for innate immunity, as it detects cytoplasmic DNA and drives type I interferon signaling. Pharmacological stimulation of this pathway has been recognized as a valuable approach for cancer immunotherapy, especially when used together with immune checkpoint inhibitors (ICIs). Preclinical studies have demonstrated synergistic antitumor effects of cGAS\u2013STING agonists and ICIs across various tumor models, while early-phase clinical trials are exploring their safety and efficacy in patients. Nonetheless, intrinsic tumor resistance, an immunosuppressive tumor microenvironment (TME), and therapy-associated immune toxicities continue to pose substantial obstacles to clinical application. In this review, we provide an overview of the present status of cGAS\u2013STING agonists, emphasizing preclinical and clinical advances in combination therapy with ICIs, and discusses the challenges and future directions to optimize efficacy, improve safety, and expand the therapeutic potential of this strategy in oncology.<\/jats:p>","DOI":"10.1186\/s13046-025-03555-9","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:10:09Z","timestamp":1762524609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Bridging innate and adaptive tumor immunity: cGAS\u2013STING pathway activation to potentiate immune checkpoint blockade"],"prefix":"10.1186","volume":"44","author":[{"given":"Zhuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"3555_CR1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11:838\u201357.","journal-title":"Cancer Discov"},{"key":"3555_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"3555_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint Blockade. Science. 2018;359:1350\u20135.","journal-title":"Science"},{"key":"3555_CR4","doi-asserted-by":"publisher","first-page":"107726","DOI":"10.1016\/j.phrs.2025.107726","volume":"215","author":"M Huang","year":"2025","unstructured":"Huang M, Zhang Y, Chen Z, Yu X, Luo S, Peng X, Li X. Gut microbiota reshapes the TNBC immune microenvironment: emerging immunotherapeutic strategies. Pharmacol Res. 2025;215:107726.","journal-title":"Pharmacol Res"},{"key":"3555_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"3555_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"3555_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint Blockade therapy. Cancer Discov. 2018;8:1069\u201386.","journal-title":"Cancer Discov"},{"key":"3555_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9\u201316.","journal-title":"Br J Cancer"},{"key":"3555_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"3555_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"key":"3555_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"3555_CR12","doi-asserted-by":"publisher","first-page":"2486519","DOI":"10.1080\/19490976.2025.2486519","volume":"17","author":"M Huang","year":"2025","unstructured":"Huang M, Ji Q, Huang H, Wang X, Wang L. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification. Gut Microbes. 2025;17:2486519.","journal-title":"Gut Microbes"},{"key":"3555_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.1229963","volume":"339","author":"J Wu","year":"2013","unstructured":"Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339:826\u201330.","journal-title":"Science"},{"key":"3555_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","volume":"21","author":"KP Hopfner","year":"2020","unstructured":"Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020;21:501\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3555_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","volume":"20","author":"M Motwani","year":"2019","unstructured":"Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet. 2019;20:657\u201374.","journal-title":"Nat Rev Genet"},{"key":"3555_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786\u201391.","journal-title":"Science"},{"key":"3555_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-biochem-061516-044813","volume":"86","author":"K Kato","year":"2017","unstructured":"Kato K, Omura H, Ishitani R, Nureki O. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. Annu Rev Biochem. 2017;86:541\u201366.","journal-title":"Annu Rev Biochem"},{"key":"3555_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461:788\u201392.","journal-title":"Nature"},{"key":"3555_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.chom.2015.07.001","volume":"18","author":"N Dobbs","year":"2015","unstructured":"Dobbs N, Burnaevskiy N, Chen D, Gonugunta VK, Alto NM, Yan N. STING activation by translocation from the ER is associated with infection and autoinflammatory disease. Cell Host Microbe. 2015;18:157\u201368.","journal-title":"Cell Host Microbe"},{"key":"3555_CR20","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1128\/JVI.00037-14","volume":"88","author":"T Abe","year":"2014","unstructured":"Abe T, Barber GN. Cytosolic-DNA-mediated, STING-dependent Proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J Virol. 2014;88:5328\u201341.","journal-title":"J Virol"},{"key":"3555_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","volume":"34","author":"MB Fuertes","year":"2013","unstructured":"Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013;34:67\u201373.","journal-title":"Trends Immunol"},{"key":"3555_CR22","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr., Gajewski TF. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11:1018\u201330.","journal-title":"Cell Rep"},{"key":"3555_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00262-017-1975-1","volume":"66","author":"T Ohkuri","year":"2017","unstructured":"Ohkuri T, Kosaka A, Ishibashi K, Kumai T, Hirata Y, Ohara K, Nagato T, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunol Immunother. 2017;66:705\u201316.","journal-title":"Cancer Immunol Immunother"},{"key":"3555_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. STING-Dependent cytosolic DNA sensing promotes Radiation-Induced type I Interferon-Dependent antitumor immunity in Immunogenic tumors. Immunity. 2014;41:843\u201352.","journal-title":"Immunity"},{"key":"3555_CR25","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","volume":"25","author":"KE Sivick","year":"2018","unstructured":"Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr., McWhirter SM. Magnitude of therapeutic STING activation determines CD8(+) T Cell-Mediated Anti-tumor immunity. Cell Rep. 2018;25:3074\u2013e30853075.","journal-title":"Cell Rep"},{"key":"3555_CR26","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1021\/acs.jmedchem.1c02197","volume":"65","author":"W Chang","year":"2022","unstructured":"Chang W, Altman MD, Lesburg CA, Perera SA, Piesvaux JA, Schroeder GK, Wyss DF, Cemerski S, Chen Y, DiNunzio E, Haidle AM, Ho T, Kariv I, Knemeyer I, Kopinja JE, Lacey BM, Laskey J, Lim J, Long BJ, Ma Y, Maddess ML, Pan BS, Presland JP, Spooner E, Steinhuebel D, Truong Q, Zhang Z, Fu J, Addona GH, Northrup AB, Parmee E, Tata JR, Bennett DJ, Cumming JN, Siu T. Trotter, discovery of MK-1454: A potent Cyclic dinucleotide stimulator of interferon genes agonist for the treatment of cancer. J Med Chem. 2022;65:5675\u201389.","journal-title":"J Med Chem"},{"key":"3555_CR27","doi-asserted-by":"crossref","unstructured":"Zhang X, Bai XC, Chen ZJ. Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway. Immunity. 2020;53:43\u201353.","DOI":"10.1016\/j.immuni.2020.05.013"},{"key":"3555_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba IIJ, Sage JV, Heymach DL, Gibbons LA, Byers. Targeting DNA damage response promotes antitumor immunity through STING-Mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646\u201361.","journal-title":"Cancer Discov"},{"key":"3555_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","volume":"19","author":"J Zheng","year":"2020","unstructured":"Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, Yin J, Zhang W, Zhou H, Liu Z. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19:133.","journal-title":"Mol Cancer"},{"key":"3555_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41577-024-01112-7","volume":"25","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zhang C. Regulation of cGAS-STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. 2025;25:425\u201344.","journal-title":"Nat Rev Immunol"},{"key":"3555_CR31","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1093\/nar\/gku569","volume":"42","author":"X Wu","year":"2014","unstructured":"Wu X, Wu FH, Wang X, Wang L, Siedow JN, Zhang W, Pei ZM. Molecular evolutionary and structural analysis of the cytosolic DNA sensor cGAS and STING. Nucleic Acids Res. 2014;42:8243\u201357.","journal-title":"Nucleic Acids Res"},{"key":"3555_CR32","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1523\/JNEUROSCI.0774-19.2019","volume":"39","author":"X Song","year":"2019","unstructured":"Song X, Ma F, Herrup K. Accumulation of cytoplasmic DNA due to ATM deficiency activates the microglial viral response system with neurotoxic consequences. J Neurosci. 2019;39:6378\u201394.","journal-title":"J Neurosci"},{"key":"3555_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/febs.15027","volume":"287","author":"MJ Genoveso","year":"2020","unstructured":"Genoveso MJ, Hisaoka M, Komatsu T, Wodrich H, Nagata K, Okuwaki M. Formation of adenovirus DNA replication compartments and viral DNA accumulation sites by host chromatin regulatory proteins including NPM1. FEBS J. 2020;287:205\u201317.","journal-title":"FEBS J"},{"key":"3555_CR34","doi-asserted-by":"crossref","unstructured":"Joshi B, Joshi JC, Mehta D. Regulation of cGAS Activity and Downstream Signaling. Cells. 2022;11(18):2812.","DOI":"10.3390\/cells11182812"},{"key":"3555_CR35","doi-asserted-by":"publisher","first-page":"1902599","DOI":"10.1002\/advs.201902599","volume":"7","author":"A Saeed","year":"2020","unstructured":"Saeed A, Ruan X, Guan H, Su J, Ouyang S. Regulation of cGAS-Mediated immune responses and immunotherapy. Adv Sci (Weinh). 2020;7:1902599.","journal-title":"Adv Sci (Weinh)"},{"key":"3555_CR36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1126\/science.abd0609","volume":"370","author":"JA Boyer","year":"2020","unstructured":"Boyer JA, Spangler CJ, Strauss JD, Cesmat AP, Liu P, McGinty RK, Zhang Q. Structural basis of nucleosome-dependent cGAS Inhibition. Science. 2020;370:450\u20134.","journal-title":"Science"},{"key":"3555_CR37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature23890","volume":"549","author":"L Andreeva","year":"2017","unstructured":"Andreeva L, Hiller B, Kostrewa D, Lassig C, de Oliveira Mann CC, Jan Drexler D, Maiser A, Gaidt M, Leonhardt H, Hornung V, Hopfner KP. cGAS senses long and HMGB\/TFAM-bound U-turn DNA by forming protein-DNA ladders. Nature. 2017;549:394\u20138.","journal-title":"Nature"},{"key":"3555_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19:136.","journal-title":"Mol Cancer"},{"key":"3555_CR39","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17:1142\u20139.","journal-title":"Nat Immunol"},{"key":"3555_CR40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.immuni.2013.10.019","volume":"39","author":"X Li","year":"2013","unstructured":"Li X, Shu C, Yi G, Chaton CT, Shelton CL, Diao J, Zuo X, Kao CC, Herr AB, Li P. Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity. 2013;39:1019\u201331.","journal-title":"Immunity"},{"key":"3555_CR41","first-page":"112","volume":"35","author":"B Briard","year":"2020","unstructured":"Briard B, Place DE, Kanneganti TD. DNA sensing in the innate immune response. Physiol (Bethesda). 2020;35:112\u201324.","journal-title":"Physiol (Bethesda)"},{"key":"3555_CR42","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.immuni.2016.04.002","volume":"44","author":"A Roers","year":"2016","unstructured":"Roers A, Hiller B, Hornung V. Recognition of endogenous nucleic acids by the innate immune system. Immunity. 2016;44:739\u201354.","journal-title":"Immunity"},{"key":"3555_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-Sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26\u201339.","journal-title":"Cancer Discov"},{"key":"3555_CR44","doi-asserted-by":"crossref","unstructured":"Hong C, Tijhuis AE, Foijer F. The cGAS Paradox: Contrasting Roles for cGAS-STING Pathway in Chromosomal Instability, Cells. 2019;8(10):1228.","DOI":"10.3390\/cells8101228"},{"key":"3555_CR45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1042\/BST20220838","volume":"51","author":"B Beernaert","year":"2023","unstructured":"Beernaert B, Parkes EE. cGAS-STING signalling in cancer: striking a balance with chromosomal instability. Biochem Soc Trans. 2023;51:539\u201355.","journal-title":"Biochem Soc Trans"},{"key":"3555_CR46","doi-asserted-by":"crossref","unstructured":"Yu Y, Liu J, Liu C, Liu R, Liu L, Yu Z, Zhuang J, Sun C. Post-Translational modifications of cGAS-STING: A critical switch for immune regulation. Cells. 2022;11(19):3043.","DOI":"10.3390\/cells11193043"},{"key":"3555_CR47","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.7150\/thno.24699","volume":"8","author":"J Laengle","year":"2018","unstructured":"Laengle J, Stift J, Bilecz A, Wolf B, Beer A, Hegedus B, Stremitzer S, Starlinger P, Tamandl D, Pils D, Bergmann M. DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to Immunogenic cell death and T cells. Theranostics. 2018;8:3198\u2013213.","journal-title":"Theranostics"},{"key":"3555_CR48","doi-asserted-by":"publisher","first-page":"1482738","DOI":"10.3389\/fimmu.2024.1482738","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Xiong Y. Targeting STING signaling for the optimal cancer immunotherapy. Front Immunol. 2024;15:1482738.","journal-title":"Front Immunol"},{"key":"3555_CR49","doi-asserted-by":"crossref","unstructured":"Benoit-Lizon I, Jacquin E, Rivera Vargas T, Richard C, Roussey A, Dal Zuffo L, Martin T, Melis A, Vinokurova D, Shahoei SH, Baeza Garcia A, Pignol C, Giorgiutti S, Carapito R, Boidot R, Vegran F, Flavell RA, Ryffel B, Nelson ER, Soulas-Sprauel P, Lawrence T, Apetoh L. CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T(H)1 and T(H)9 cells. J Immunother Cancer. 2022;10(1):e003459.","DOI":"10.1136\/jitc-2021-003459"},{"key":"3555_CR50","doi-asserted-by":"crossref","unstructured":"Li W, Lu L, Lu J, Wang X, Yang C, Jin J, Wu L, Hong X, Li F, Cao D, Yang Y, Wu M, Su B, Cheng J, Yang X, Di W, Deng L. cGAS-STING-mediated DNA sensing maintains CD8(+) T cell stemness and promotes antitumor T cell therapy. Sci Transl Med. 2020;12(549):eaay9013.","DOI":"10.1126\/scitranslmed.aay9013"},{"key":"3555_CR51","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","volume":"54","author":"A de Mingo Pulido","year":"2021","unstructured":"de Mingo Pulido A, Hanggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, Mohamed E, Trillo-Tinoco J, Osunmakinde O, Pena R, Onimus A, Kaisho T, Kaufmann J, McEachern K, Soliman H, Luca VC, Rodriguez PC, Yu X, Ruffell B. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021;54:1154\u2013e11671157.","journal-title":"Immunity"},{"key":"3555_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45\u201356.","journal-title":"Nature"},{"key":"3555_CR53","doi-asserted-by":"crossref","unstructured":"Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y, Wilhelm J, Cao J, Huang G, Zhang J, Sumer B, Lea J, Lu Z, Gao J, Luo M. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. J Immunother Cancer. 2022;10(5):e003960.","DOI":"10.1136\/jitc-2021-003960"},{"key":"3555_CR54","doi-asserted-by":"crossref","unstructured":"Anastasiou M, Newton GA, Kaur K, Carrillo-Salinas FJ, Smolgovsky SA, Bayer AL, Ilyukha V, Sharma S, Poltorak A, Luscinskas FW, Alcaide P. Endothelial STING controls T cell transmigration in an IFNI-dependent manner. JCI Insight. 2021;6(15):e149346.","DOI":"10.1172\/jci.insight.149346"},{"key":"3555_CR55","doi-asserted-by":"publisher","first-page":"15408","DOI":"10.1073\/pnas.1512832112","volume":"112","author":"O Demaria","year":"2015","unstructured":"Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, Martinon F, Modlin RL, Speiser DE, Gilliet M. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2015;112:15408\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3555_CR56","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3389\/fimmu.2020.02090","volume":"11","author":"M Campisi","year":"2020","unstructured":"Campisi M, Sundararaman SK, Shelton SE, Knelson EH, Mahadevan NR, Yoshida R, Tani T, Ivanova E, Canadas I, Osaki T, Lee SWL, Thai T, Han S, Piel BP, Gilhooley S, Paweletz CP, Chiono V, Kamm RD, Kitajima S, Barbie DA. Tumor-Derived cGAMP regulates activation of the vasculature. Front Immunol. 2020;11:2090.","journal-title":"Front Immunol"},{"key":"3555_CR57","doi-asserted-by":"crossref","unstructured":"Lee SJ, Yang H, Kim WR, Lee YS, Lee WS, Kong SJ, Lee HJ, Kim JH, Cheon J, Kang B, Chon HJ, Kim C. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. J Immunother Cancer. 2021;9(6):e002195.","DOI":"10.1136\/jitc-2020-002195"},{"key":"3555_CR58","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1172\/JCI125413","volume":"129","author":"H Yang","year":"2019","unstructured":"Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, Kim S, Kim G, Chon HJ, Kim C. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 Blockade. J Clin Invest. 2019;129:4350\u201364.","journal-title":"J Clin Invest"},{"key":"3555_CR59","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1042\/EBC20220244","volume":"67","author":"AL Young","year":"2023","unstructured":"Young AL, Lorimer T, Al-Khalidi SK, Roberts EW. De Novo priming: driver of immunotherapy responses or epiphenomenon? Essays Biochem. 2023;67:929\u201339.","journal-title":"Essays Biochem"},{"key":"3555_CR60","doi-asserted-by":"crossref","unstructured":"Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers (Basel). 2021;13(1):134.","DOI":"10.3390\/cancers13010134"},{"key":"3555_CR61","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","volume":"33","author":"RH Vonderheide","year":"2018","unstructured":"Vonderheide RH. The immune revolution: A case for Priming, not checkpoint. Cancer Cell. 2018;33:563\u20139.","journal-title":"Cancer Cell"},{"key":"3555_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","volume":"12","author":"A Li","year":"2019","unstructured":"Li A, Yi M, Qin S, Song Y, Chu Q, Wu K. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol. 2019;12:35.","journal-title":"J Hematol Oncol"},{"key":"3555_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","volume":"81","author":"G Li","year":"2024","unstructured":"Li G, Zhao X, Zheng Z, Zhang H, Wu Y, Shen Y, Chen Q. cGAS-STING pathway mediates activation of dendritic cell sensing of Immunogenic tumors. Cell Mol Life Sci. 2024;81:149.","journal-title":"Cell Mol Life Sci"},{"key":"3555_CR64","doi-asserted-by":"publisher","first-page":"101729","DOI":"10.1016\/j.smim.2023.101729","volume":"66","author":"FM Cruz","year":"2023","unstructured":"Cruz FM, Chan A, Rock KL. Pathways of MHC I cross-presentation of exogenous antigens. Semin Immunol. 2023;66:101729.","journal-title":"Semin Immunol"},{"key":"3555_CR65","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF. STING-dependent cytosolic DNA sensing mediates innate immune recognition of Immunogenic tumors. Immunity. 2014;41:830\u201342.","journal-title":"Immunity"},{"key":"3555_CR66","doi-asserted-by":"crossref","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity. 2018;49:e754\u2013763.","DOI":"10.1016\/j.immuni.2018.09.016"},{"key":"3555_CR67","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.canlet.2020.11.005","volume":"501","author":"M Huang","year":"2021","unstructured":"Huang M, Peng X, Yang L, Yang S, Li X, Tang S, Li B, Jin H, Wu B, Liu J, Li H. Non-coding RNA derived from extracellular vesicles in cancer immune escape: biological functions and potential clinical applications. Cancer Lett. 2021;501:234\u201346.","journal-title":"Cancer Lett"},{"key":"3555_CR68","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2326-6066.CIR-17-0581","volume":"6","author":"JM Diamond","year":"2018","unstructured":"Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, Pilones KA, Sarfraz Y, Formenti SC, Demaria S. Exosomes shuttle TREX1-Sensitive IFN-Stimulatory DsDNA from irradiated cancer cells to DCs. Cancer Immunol Res. 2018;6:910\u201320.","journal-title":"Cancer Immunol Res"},{"key":"3555_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CJI.0000000000000195","volume":"41","author":"MF Laursen","year":"2018","unstructured":"Laursen MF, Christensen E, Degn LLT, Jonsson K, Jakobsen MR, Agger R, Kofod-Olsen E. CD11c-targeted delivery of DNA to dendritic cells leads to cGAS- and STING-dependent maturation. J Immunother. 2018;41:9\u201318.","journal-title":"J Immunother"},{"key":"3555_CR70","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00262-019-02400-1","volume":"68","author":"M Fyrstenberg Laursen","year":"2019","unstructured":"Fyrstenberg Laursen M, Kofod-Olsen E, Agger R. Activation of dendritic cells by targeted DNA: a potential addition to the armamentarium for anti-cancer immunotherapy. Cancer Immunol Immunother. 2019;68:1875\u201380.","journal-title":"Cancer Immunol Immunother"},{"key":"3555_CR71","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27:1482\u201392.","journal-title":"Ann Oncol"},{"key":"3555_CR72","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Myeloid-Derived suppressor cells hinder the Anti-Cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310.","journal-title":"Front Immunol"},{"key":"3555_CR73","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:72.","journal-title":"Signal Transduct Target Ther"},{"key":"3555_CR74","doi-asserted-by":"publisher","first-page":"1383456","DOI":"10.3389\/fimmu.2024.1383456","volume":"15","author":"SA Javed","year":"2024","unstructured":"Javed SA, Najmi A, Ahsan W, Zoghebi K. Targeting PD-1\/PD-L-1 immune checkpoint Inhibition for cancer immunotherapy: success and challenges. Front Immunol. 2024;15:1383456.","journal-title":"Front Immunol"},{"key":"3555_CR75","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-019-1553-0","volume":"573","author":"RD Luteijn","year":"2019","unstructured":"Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, McWhirter SM, Katibah GE, Corn JE, Woodward JJ, Raulet DH. SLC19A1 transports immunoreactive Cyclic dinucleotides. Nature. 2019;573:434\u20138.","journal-title":"Nature"},{"key":"3555_CR76","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.molcel.2019.05.006","volume":"75","author":"C Ritchie","year":"2019","unstructured":"Ritchie C, Cordova AF, Hess GT, Bassik MC, Li L. SLC19A1 is an importer of the Immunotransmitter cGAMP. Mol Cell. 2019;75:372\u2013e381375.","journal-title":"Mol Cell"},{"key":"3555_CR77","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1021\/acscentsci.1c00440","volume":"7","author":"AF Cordova","year":"2021","unstructured":"Cordova AF, Ritchie C, Bohnert V, Li L. Human SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-Sensing macrophages and monocytes. ACS Cent Sci. 2021;7:1073\u201388.","journal-title":"ACS Cent Sci"},{"key":"3555_CR78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s43018-020-0028-4","volume":"1","author":"JA Carozza","year":"2020","unstructured":"Carozza JA, Bohnert V, Nguyen KC, Skariah G, Shaw KE, Brown JA, Rafat M, von Eyben R, Graves EE, Glenn JS, Smith M, Li L. Extracellular cGAMP is a cancer cell-produced Immunotransmitter involved in radiation-induced anti-cancer immunity. Nat Cancer. 2020;1:184\u201396.","journal-title":"Nat Cancer"},{"key":"3555_CR79","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3389\/fonc.2020.00896","volume":"10","author":"H Cheng","year":"2020","unstructured":"Cheng H, Xu Q, Lu X, Yuan H, Li T, Zhang Y, Tan X. Activation of STING by cGAMP regulates MDSCs to suppress tumor metastasis via reversing Epithelial-Mesenchymal transition. Front Oncol. 2020;10:896.","journal-title":"Front Oncol"},{"key":"3555_CR80","doi-asserted-by":"crossref","unstructured":"Ager CR, Boda A, Rajapakshe K, Lea ST, Di Francesco ME, Jayaprakash P, Slay RB, Morrow B, Prasad R, Dean MA, Duffy CR, Coarfa C, Jones P, Curran MA. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. J Immunother Cancer. 2021;9(8):e003246.","DOI":"10.1136\/jitc-2021-003246"},{"key":"3555_CR81","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1038\/s41418-019-0302-0","volume":"26","author":"CX Zhang","year":"2019","unstructured":"Zhang CX, Ye SB, Ni JJ, Cai TT, Liu YN, Huang DJ, Mai HQ, Chen QY, He J, Zhang XS, Zeng YX, Li J, Cui J. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 2019;26:2314\u201328.","journal-title":"Cell Death Differ"},{"key":"3555_CR82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.canlet.2019.02.029","volume":"450","author":"J Pei","year":"2019","unstructured":"Pei J, Zhang Y, Luo Q, Zheng W, Li W, Zeng X, Li Q, Quan J. STAT3 Inhibition enhances CDN-induced STING signaling and antitumor immunity. Cancer Lett. 2019;450:110\u201322.","journal-title":"Cancer Lett"},{"key":"3555_CR83","doi-asserted-by":"publisher","first-page":"eadk2612","DOI":"10.1126\/sciimmunol.adk2612","volume":"9","author":"R Zhao","year":"2024","unstructured":"Zhao R, Zhang J, Ma J, Qu Y, Yang Z, Yin Z, Li F, Dong Z, Sun Q, Zhu S, Chen ZJ, Gao D. cGAS-activated endothelial cell-T cell cross-talk initiates tertiary lymphoid structure formation. Sci Immunol. 2024;9:eadk2612.","journal-title":"Sci Immunol"},{"issue":"2","key":"3555_CR84","doi-asserted-by":"publisher","first-page":"e001906","DOI":"10.1136\/jitc-2020-001906","volume":"9","author":"M Chelvanambi","year":"2021","unstructured":"Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer. 2021;9(2):e001906.","journal-title":"J Immunother Cancer"},{"key":"3555_CR85","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li S, Mirlekar B, Johnson BM, Brickey WJ, Wrobel JA, Yang N, Song D, Entwistle S, Tan X, Deng M, Cui Y, Li W, Vincent BG, Gale M Jr., Pylayeva-Gupta Y, Ting JP. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature. 2022;610:373\u201380.","journal-title":"Nature"},{"key":"3555_CR86","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-17-2807","volume":"24","author":"YS Tan","year":"2018","unstructured":"Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile E, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, Nor JE, Ferris RL, Wolf GT, Sun D, Lei YL. Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine. Clin Cancer Res. 2018;24:4242\u201355.","journal-title":"Clin Cancer Res"},{"key":"3555_CR87","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.nano.2017.10.013","volume":"14","author":"DR Wilson","year":"2018","unstructured":"Wilson DR, Sen R, Sunshine JC, Pardoll DM, Green JJ, Kim YJ. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine. 2018;14:237\u201346.","journal-title":"Nanomedicine"},{"key":"3555_CR88","doi-asserted-by":"publisher","first-page":"283ra252","DOI":"10.1126\/scitranslmed.aaa4306","volume":"7","author":"J Fu","year":"2015","unstructured":"Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, Sivick KE, Zeng Q, Soares KC, Zheng L, Portnoy DA, Woodward JJ, Pardoll DM, Dubensky TW Jr., Kim Y. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 Blockade. Sci Transl Med. 2015;7:283ra252.","journal-title":"Sci Transl Med"},{"key":"3555_CR89","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","volume":"14","author":"D Shae","year":"2019","unstructured":"Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, Ascano M, Kelley M, Johnson DB, Balko JM, Wilson JT. Endosomolytic polymersomes increase the activity of Cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019;14:269\u201378.","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"3555_CR90","doi-asserted-by":"publisher","first-page":"e002852","DOI":"10.1136\/jitc-2021-002852","volume":"9","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, Hyodo M, Hayakawa Y, Harashima H. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer. 2021;9(7):e002852.","journal-title":"J Immunother Cancer"},{"key":"3555_CR91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","volume":"10","author":"CY Ok","year":"2017","unstructured":"Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017;10:103.","journal-title":"J Hematol Oncol"},{"key":"3555_CR92","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548:466\u201370.","journal-title":"Nature"},{"key":"3555_CR93","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1158\/2326-6066.CIR-17-0049","volume":"5","author":"CR Ager","year":"2017","unstructured":"Ager CR, Reilley MJ, Nicholas C, Bartkowiak T, Jaiswal AR, Curran MA. Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol Res. 2017;5:676\u201384.","journal-title":"Cancer Immunol Res"},{"key":"3555_CR94","doi-asserted-by":"crossref","unstructured":"Motedayen Aval L, Pease JE, Sharma R, Pinato DJ. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med. 2020;9(10):3323.","DOI":"10.3390\/jcm9103323"},{"key":"3555_CR95","doi-asserted-by":"publisher","first-page":"292","DOI":"10.18632\/oncotarget.27886","volume":"12","author":"AH Zaidi","year":"2021","unstructured":"Zaidi AH, Kelly RJ, Gorbunova A, Omstead AN, Salvitti MS, Zheng P, Kosovec JE, Lee S, Ayazi S, Babar L, Finley GG, Goel A, Jobe BA. Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8\u2009+\u2009T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model. Oncotarget. 2021;12:292\u2013303.","journal-title":"Oncotarget"},{"key":"3555_CR96","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","volume":"29","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Muller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S. Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor Spartalizumab in Advanced\/Metastatic solid tumors or lymphomas: an Open-Label, Multicenter, phase Ib study. Clin Cancer Res. 2023;29:110\u201321.","journal-title":"Clin Cancer Res"},{"key":"3555_CR97","doi-asserted-by":"publisher","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","volume":"29","author":"K Harrington","year":"2018","unstructured":"Harrington K, Brody J, Ingham M, Strauss J, Cemerski S, Wang M, Tse A, Khilnani A, Marabelle A, Golan T. Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Ann Oncol. 2018;29:viii712.","journal-title":"Ann Oncol"},{"issue":"16","key":"3555_CR98","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1158\/1078-0432.CCR-24-3630","volume":"31","author":"KJ Harrington","year":"2025","unstructured":"Harrington KJ, Champiat S, Brody JD, Cho BC, Romano E, Golan T, Hyngstrom JR, Strauss J, Oh DY, Popovtzer A, Gomez-Roca C, Perets R, Kim SB, Wong DJ, Powell SF, Khilnani A, Jemielita T, Zhao Q, Zhao R, Ingham M. Phase 1 and 2 clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas. Clin Cancer Res. 2025;31(16):3400\u201311.","journal-title":"Clin Cancer Res"},{"key":"3555_CR99","doi-asserted-by":"crossref","unstructured":"Li A, Gonda BL, Codd EM, von Paternos A, Mitchell DR, Herrmann MD, Kalyan P, Flynn SE, Dzu TQ, Gao C, Zhang E, Mendel JJ, Thierauf JC, Sadow PM, Denize T, Yang D, Fintelmann FJ, Fordham JA, Merkin RD, Bhan AK, Huang YC, Raizer J, Faquin WC, Faden DL, Gao X, Park JC, Wirth LJ, Kaluziak ST, Iafrate AJ. Reversible downregulation of HLA class I in adenoid cystic carcinoma. J Immunother Cancer. 2025;13(4):e011380.","DOI":"10.1136\/jitc-2024-011380"},{"key":"3555_CR100","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-24-2824","volume":"31","author":"JJ Luke","year":"2025","unstructured":"Luke JJ, Sweis RF, Hecht JR, Schneider R, Stein MN, Golan T, Yap TA, Khilnani A, Huang M, Zhao R, Jemielita T, Patel SP. Intratumoral or subcutaneous MK-2118, a noncyclic dinucleotide STING Agonist, with or without Pembrolizumab, for advanced or metastatic solid tumors or lymphomas. Clin Cancer Res. 2025;31:1233\u201342.","journal-title":"Clin Cancer Res"},{"key":"3555_CR101","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature18268","volume":"533","author":"Q Chen","year":"2016","unstructured":"Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, Jacob L, Patwa R, Shah H, Xu K, Cross JR, Massague J. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016;533:493\u20138.","journal-title":"Nature"},{"key":"3555_CR102","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1158\/0008-5472.CAN-23-0046","volume":"83","author":"DK Nambiar","year":"2023","unstructured":"Nambiar DK, Viswanathan V, Cao H, Zhang W, Guan L, Chamoli M, Holmes B, Kong C, Hildebrand R, Koong AJ, von Eyben R, Plevritis S, Li L, Giaccia A, Engleman E, Le QT. Galectin-1 mediates chronic STING activation in tumors to promote metastasis through MDSC recruitment. Cancer Res. 2023;83:3205\u201319.","journal-title":"Cancer Res"},{"key":"3555_CR103","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1016\/j.bbadis.2015.08.011","volume":"1852","author":"D Liang","year":"2015","unstructured":"Liang D, Xiao-Feng H, Guan-Jun D, Er-Ling H, Sheng C, Ting-Ting W, Qin-Gang H, Yan-Hong N. Ya-Yi, activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun\/CCL22 signal. Biochim Biophys Acta. 2015;1852:2494\u2013503.","journal-title":"Biochim Biophys Acta"},{"key":"3555_CR104","doi-asserted-by":"crossref","unstructured":"Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, Duran M, Pauli C, Shaw C, Chadalavada K, Rajasekhar VK, Genovese G, Venkatesan S, Birkbak NJ, McGranahan N, Lundquist M, LaPlant Q, Healey JH, Elemento O, Chung CH, Lee NY, Imielenski M, Nanjangud G, Pe\u2019er D, Cleveland DW, Powell SN, Lammerding J, Swanton C, L.C., Cantley. Chromosomal instability drives metastasis through a cytosolic DNA response, Nature. 2018;553:467\u2013472.","DOI":"10.1038\/nature25432"},{"key":"3555_CR105","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","volume":"620","author":"J Li","year":"2023","unstructured":"Li J, Hubisz MJ, Earlie EM, Duran MA, Hong C, Varela AA, Lettera E, Deyell M, Tavora B, Havel JJ, Phyu SM, Amin AD, Budre K, Kamiya E, Cavallo JA, Garris C, Powell S, Reis-Filho JS, Wen H, Bettigole S, Khan AJ, Izar B, Parkes EE, Laughney AM, Bakhoum SF. Non-cell-autonomous cancer progression from chromosomal instability. Nature. 2023;620:1080\u20138.","journal-title":"Nature"},{"key":"3555_CR106","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41388-017-0120-0","volume":"37","author":"H Konno","year":"2018","unstructured":"Konno H, Yamauchi S, Berglund A, Putney RM, Mule JJ, Barber GN. Suppression of STING signaling through epigenetic Silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene. 2018;37:2037\u201351.","journal-title":"Oncogene"},{"key":"3555_CR107","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/2326-6066.CIR-23-1078","volume":"12","author":"J Lim","year":"2024","unstructured":"Lim J, Rodriguez R, Williams K, Silva J, Gutierrez AG, Tyler P, Baharom F, Sun T, Lin E, Martin S, Kayser BD, Johnston RJ, Mellman I, Delamarre L, West NR, Muller S, Qu Y, Heger K. The exonuclease TREX1 constitutes an innate immune checkpoint limiting cGAS\/STING-Mediated antitumor immunity. Cancer Immunol Res. 2024;12:663\u201372.","journal-title":"Cancer Immunol Res"},{"key":"3555_CR108","doi-asserted-by":"publisher","first-page":"277","DOI":"10.7150\/thno.101001","volume":"15","author":"A Deng","year":"2025","unstructured":"Deng A, Fan R, Hai Y, Zhuang J, Zhang B, Lu X, Wang W, Luo L, Bai G, Liang L, Yang L, Zhao M, Wei G. A STING agonist prodrug reprograms tumor-associated macrophage to boost colorectal cancer immunotherapy. Theranostics. 2025;15:277\u201399.","journal-title":"Theranostics"},{"key":"3555_CR109","doi-asserted-by":"publisher","first-page":"e70211","DOI":"10.1111\/jcmm.70211","volume":"28","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Gao Y, Wang J, Tan X, Liang Y, Yu W, Deng Z, Zhou J, Ye Z, Luo G. Connexin 43 deficiency confers resistance to immunotherapy in lung cancer via Inhibition of the Cyclic GMP-AMP Synthase-Stimulator of interferon genes pathway. J Cell Mol Med. 2024;28:e70211.","journal-title":"J Cell Mol Med"},{"key":"3555_CR110","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/s41467-024-46504-4","volume":"15","author":"MT Broz","year":"2024","unstructured":"Broz MT, Ko EY, Ishaya K, Xiao J, De Simone M, Hoi XP, Piras R, Gala B, Tessaro FHG, Karlstaedt A, Orsulic S, Lund AW, Chan KS, Guarnerio J. Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas. Nat Commun. 2024;15:2498.","journal-title":"Nat Commun"},{"key":"3555_CR111","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, Kopp M, Li Y, Pattada N, Zhong W, Guo W, Scholler J, Liousia M, Assenmacher CA, June CH, Albelda SM, Pure E. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun. 2023;14:5110.","journal-title":"Nat Commun"},{"key":"3555_CR112","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12964-023-01466-w","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Zhou J, Luan Y, Li X, Meng X, Liao W, Tang J, Wang Z. cGAS-STING, inflammasomes and pyroptosis: an overview of crosstalk mechanism of activation and regulation. Cell Commun Signal. 2024;22:22.","journal-title":"Cell Commun Signal"},{"key":"3555_CR113","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","volume":"36","author":"SR Woo","year":"2015","unstructured":"Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015;36:250\u20136.","journal-title":"Trends Immunol"},{"key":"3555_CR114","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41419-022-04664-5","volume":"13","author":"Y Messaoud-Nacer","year":"2022","unstructured":"Messaoud-Nacer Y, Culerier E, Rose S, Maillet I, Rouxel N, Briault S, Ryffel B, Quesniaux VFJ, Togbe D. STING agonist DiABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS). Cell Death Dis. 2022;13:269.","journal-title":"Cell Death Dis"},{"key":"3555_CR115","doi-asserted-by":"crossref","unstructured":"Pacha O, Patel AB, Curry JL, Haymaker CL, Ozirmak Lermi N, Duose DY, Chen K, Hajjar J, Naing A. Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors. J Immunother Cancer. 2025;13(8):e011401.","DOI":"10.1136\/jitc-2024-011401"},{"key":"3555_CR116","first-page":"2335","volume":"131","author":"DM Jones","year":"1985","unstructured":"Jones DM, Curry A, Fox AJ. An ultrastructural study of the gastric campylobacter-like organism \u2018Campylobacter pyloridis\u2019. J Gen Microbiol. 1985;131:2335\u201341.","journal-title":"J Gen Microbiol"},{"key":"3555_CR117","doi-asserted-by":"crossref","unstructured":"Yu X, Cai L, Yao J, Li C, Wang X. Agonists and Inhibitors of the cGAS-STING Pathway, Molecules.\u00a02024;29.","DOI":"10.3390\/molecules29133121"},{"key":"3555_CR118","doi-asserted-by":"crossref","unstructured":"Wang Z, Wang Y, He Z, Liu C. Emerging cGAS-STING Agonist-Based nanotherapeutics: mechanistic insights and applications in cancer combination therapy. Adv Sci (Weinh). 202;12(36):e09890.","DOI":"10.1002\/advs.202509890"},{"key":"3555_CR119","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41467-020-16602-0","volume":"11","author":"DS Leventhal","year":"2020","unstructured":"Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, Gallant CW, Christmas R, Gao JR, James MJ, Abin-Fuentes A, Momin M, Bergeron C, Fisher A, Miller PF, West KA, Lora JM. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020;11:2739.","journal-title":"Nat Commun"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03555-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03555-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03555-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:06:13Z","timestamp":1762527973000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03555-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3555"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03555-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"16 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}